Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Top signal score 37 of 100
Buys €429,914n/a Sells
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 25,291 of 26,284 companies
13.6
score / 100
Value
20
Quality
8
FCF yld-14%
Earn yld-1.9%
EV/EBITDA·
ROE-17%
Gross mgn-20%
Net mgn-20%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
10,000 shares@ CN¥24.55176.5% of flowA股XSHGSSE:273000001486021630
Canonical exit: 10 Dec 2026 (T+90)
25 of 27 declarations
About Ningxia Zhongke Biotechnology Co., Ltd
At 宁科生物 (Ningxia Zhongke Biotechnology Co., Ltd), a Chinese chemicals and materials company listed on the Shanghai stock exchange, all 24 filings on record are purchases, published from September 3, 2026 to October 20, 2026. They total EUR 420,073, with a median of EUR 8,467. No sale is recorded.
The three largest purchases are by the same director: EUR 85,650 on October 9, 2026, EUR 58,513 on October 14, 2026 and EUR 41,313 on September 11, 2026. From September 21 to October 20, 2026, 7 insiders bought for EUR 267,357. Across the full history, 24 purchase filings are classed as clustered. The three most active directors file 6, 6 and 5 filings, all purchases, and two other insiders, a director who is also an executive and a senior manager, file 2 each.
Read moreShow less
The company is valued at CNY 4.9 billion, and its 7 insiders hold 58.7% of the capital. The record is recent: everything falls in 2026, hence within the last twelve months. The median publication delay is 0 days, meaning the day of the trade.
Over the last 90 days, 27 filings published between 3 September and 22 October 2026: 27 open-market purchases by insiders for €430k. Largest amounts: 刘喜荣 (董事), purchases of €225k; 符杰 (董事), purchases of €63k; 屈晓春 (高级管理人员), purchases of €41k.
Summary written automatically from public filings, without human review. General information, identical for every reader: it is not investment advice or a recommendation to buy or sell. Investing involves a risk of capital loss. Generated on 23 October 2026 (UTC)